Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COGT NASDAQ:PTCT NYSE:TRLV NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$40.67+0.6%$36.04$10.38▼$43.73$6.95B0.342.26 million shs1.13 million shsPTCTPTC Therapeutics$75.39-0.5%$77.40$43.17▼$90.87$6.25B0.531.46 million shs1.49 million shsTRLVTrulieve Cannabis$8.33+0.0%$0.00$4.19▼$13.28$1.60BN/A632,581 shs783,166 shsXENEXenon Pharmaceuticals$64.94-1.3%$58.76$30.00▼$72.66$6.28B0.611.35 million shs485,005 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences+1.71%+5.59%+6.10%+11.28%+235.05%PTCTPTC Therapeutics-1.33%-2.83%-10.22%+7.88%+69.42%TRLVTrulieve Cannabis-0.51%-4.58%-6.68%+832,899,900.00%+832,899,900.00%XENEXenon Pharmaceuticals+0.55%-0.39%+10.11%+20.63%+117.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$40.67+0.6%$36.04$10.38▼$43.73$6.95B0.342.26 million shs1.13 million shsPTCTPTC Therapeutics$75.39-0.5%$77.40$43.17▼$90.87$6.25B0.531.46 million shs1.49 million shsTRLVTrulieve Cannabis$8.33+0.0%$0.00$4.19▼$13.28$1.60BN/A632,581 shs783,166 shsXENEXenon Pharmaceuticals$64.94-1.3%$58.76$30.00▼$72.66$6.28B0.611.35 million shs485,005 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences+1.71%+5.59%+6.10%+11.28%+235.05%PTCTPTC Therapeutics-1.33%-2.83%-10.22%+7.88%+69.42%TRLVTrulieve Cannabis-0.51%-4.58%-6.68%+832,899,900.00%+832,899,900.00%XENEXenon Pharmaceuticals+0.55%-0.39%+10.11%+20.63%+117.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences 2.85Moderate Buy$45.9012.86% UpsidePTCTPTC Therapeutics 2.80Moderate Buy$92.2922.41% UpsideTRLVTrulieve Cannabis 2.00Hold$15.0079.99% UpsideXENEXenon Pharmaceuticals 3.00Buy$77.2018.88% UpsideCurrent Analyst Ratings BreakdownLatest TRLV, COGT, PTCT, and XENE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026PTCTPTC Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$95.00 ➝ $93.007/20/2026TRLVTrulieve Cannabis Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$15.007/16/2026PTCTPTC Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$124.00 ➝ $130.007/8/2026COGTCogent Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/7/2026PTCTPTC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$82.00 ➝ $85.007/7/2026PTCTPTC Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/6/2026XENEXenon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/18/2026TRLVTrulieve Cannabis Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/16/2026TRLVTrulieve Cannabis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (D-)6/9/2026PTCTPTC Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$75.00 ➝ $108.005/29/2026COGTCogent Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.00(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$3.84 per shareN/APTCTPTC Therapeutics$1.73B3.61$8.62 per share8.75($2.56) per share-29.45TRLVTrulieve Cannabis$1.17B1.37N/AN/AN/A∞XENEXenon Pharmaceuticals$7.50M837.03N/AN/A$7.53 per share8.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A35.396.69-22.58%-362.45%-6.76%7/30/2026 (Estimated)TRLVTrulieve CannabisN/AN/AN/AN/AN/AN/AN/AN/AN/AXENEXenon Pharmaceuticals-$345.91M-$4.70N/AN/AN/AN/A-49.23%-46.42%8/10/2026 (Estimated)Latest TRLV, COGT, PTCT, and XENE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026XENEXenon Pharmaceuticals-$1.16N/AN/AN/A$1.67 millionN/A8/4/2026Q2 2026COGTCogent Biosciences-$0.55N/AN/AN/A$0.00 millionN/A7/30/2026Q2 2026PTCTPTC Therapeutics$0.22N/AN/AN/A$298.63 millionN/A5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/7/2026Q1 2026XENEXenon Pharmaceuticals-$1.17-$1.17N/A-$1.17$1.36 millionN/A5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ATRLVTrulieve CannabisN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent Biosciences0.4115.1415.14PTCTPTC TherapeuticsN/A2.442.36TRLVTrulieve CannabisN/AN/AN/AXENEXenon PharmaceuticalsN/A27.7927.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/APTCTPTC TherapeuticsN/ATRLVTrulieve CannabisN/AXENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences6.59%PTCTPTC Therapeutics5.50%TRLVTrulieve Cannabis3.79%XENEXenon Pharmaceuticals2.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences80170.87 million159.61 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableTRLVTrulieve Cannabis9,000192.31 millionN/AN/AXENEXenon Pharmaceuticals21096.67 million93.85 millionOptionableTRLV, COGT, PTCT, and XENE HeadlinesRecent News About These CompaniesXenon Pharmaceuticals Inc. $XENE is Rock Springs Capital Management LP's 9th Largest PositionJuly 28 at 6:56 AM | marketbeat.comEversept Partners LP Lowers Holdings in Xenon Pharmaceuticals Inc. $XENEJuly 28 at 6:31 AM | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Purchased by Swiss National BankJuly 28 at 4:16 AM | marketbeat.com64,563 Shares in Xenon Pharmaceuticals Inc. $XENE Purchased by Castleark Management LLCJuly 28 at 3:43 AM | marketbeat.comOrbimed Advisors LLC Acquires 612,771 Shares of Xenon Pharmaceuticals Inc. $XENEJuly 27 at 6:08 AM | marketbeat.comOctagon Capital Advisors LP Purchases Shares of 490,000 Xenon Pharmaceuticals Inc. $XENEJuly 27 at 5:52 AM | marketbeat.comCommodore Capital LP Trims Position in Xenon Pharmaceuticals Inc. $XENEJuly 27 at 4:15 AM | marketbeat.comAffinity Asset Advisors LLC Buys 425,000 Shares of Xenon Pharmaceuticals Inc. $XENEJuly 25 at 3:12 AM | marketbeat.comSiren L.L.C. Has $76.67 Million Stock Holdings in Xenon Pharmaceuticals Inc. $XENEJuly 24, 2026 | marketbeat.comHsbc Holdings PLC Purchases New Position in Xenon Pharmaceuticals Inc. $XENEJuly 24, 2026 | marketbeat.comAtika Capital Management LLC Has $3.48 Million Stake in Xenon Pharmaceuticals Inc. $XENEJuly 24, 2026 | marketbeat.comKBC Group NV Raises Stock Holdings in Xenon Pharmaceuticals Inc. $XENEJuly 23, 2026 | marketbeat.comAllspring Global Investments Holdings LLC Takes $13.96 Million Position in Xenon Pharmaceuticals Inc. $XENEJuly 22, 2026 | marketbeat.comJennison Associates LLC Has $76.69 Million Stake in Xenon Pharmaceuticals Inc. $XENEJuly 20, 2026 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by AnalystsJuly 20, 2026 | americanbankingnews.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by BrokeragesJuly 20, 2026 | marketbeat.comXenon Pharmaceuticals: Azetukalner Has Shifted From Binary Science To Commercial ExecutionJuly 16, 2026 | seekingalpha.comTeachers Retirement System of The State of Kentucky Acquires New Shares in Xenon Pharmaceuticals Inc. $XENEJuly 16, 2026 | marketbeat.comCalamos Advisors LLC Makes New Investment in Xenon Pharmaceuticals Inc. $XENEJuly 16, 2026 | marketbeat.com26,200 Shares in Xenon Pharmaceuticals Inc. $XENE Bought by Swedbank ABJuly 12, 2026 | marketbeat.comCandriam S.C.A. Has $27.71 Million Stock Holdings in Xenon Pharmaceuticals Inc. $XENEJuly 12, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRLV, COGT, PTCT, and XENE Company DescriptionsCogent Biosciences NASDAQ:COGT$40.67 +0.23 (+0.57%) Closing price 04:00 PM EasternExtended Trading$40.66 -0.01 (-0.01%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.PTC Therapeutics NASDAQ:PTCT$75.39 -0.41 (-0.54%) Closing price 04:00 PM EasternExtended Trading$75.39 0.00 (-0.01%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Trulieve Cannabis NYSE:TRLV$8.33 +0.00 (+0.05%) Closing price 03:59 PM EasternExtended Trading$8.32 -0.02 (-0.23%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.Xenon Pharmaceuticals NASDAQ:XENE$64.94 -0.84 (-1.28%) Closing price 04:00 PM EasternExtended Trading$66.03 +1.09 (+1.67%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
